Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
October 3rd, 2019
11.1K views
The chronic administration of isoproterenol via an implanted osmotic pump has been used widely to mimic advanced heart failure in mice. Here, we describe detailed methods in surgical mini-pump implantation for the continuous isoproterenol administration over 3 weeks, as well as, echocardiographic assessment for the successful model creation.
Overview
This article describes a method for chronic administration of isoproterenol via an osmotic pump to model advanced heart failure in mice. The procedure is straightforward and requires less surgical expertise compared to other models.
Key Study Components
Area of Science
- Cardiovascular research
- Animal models of disease
- Pharmacological interventions
Background
- Isoproterenol is commonly used to induce heart failure in research settings.
- Chronic administration mimics the progression of heart failure.
- Osmotic pumps provide a continuous delivery method.
- This model is less invasive than traditional surgical techniques.
Purpose of Study
- To establish a reliable model of advanced heart failure in mice.
- To demonstrate the surgical implantation of osmotic pumps.
- To assess the efficacy of the model through echocardiographic evaluation.
Methods Used
- Implantation of osmotic pumps for continuous isoproterenol delivery.
- Preparation of isoproterenol solution for administration.
- Monitoring of body weight and pump setup for each mouse.
- Echocardiographic assessment to evaluate heart function.
Main Results
- The method successfully mimics advanced heart failure in mice.
- Continuous delivery of isoproterenol was achieved over three weeks.
- Echocardiographic results confirmed the model's effectiveness.
- The procedure is accessible for researchers with varying surgical skills.
Conclusions
- This model provides a useful tool for studying heart failure mechanisms.
- The simplicity of the method encourages broader use in research.
- Future studies can build on this model to explore therapeutic interventions.
Frequently Asked Questions
What is the significance of using isoproterenol in this study?
Isoproterenol is used to induce heart failure symptoms in mice, allowing researchers to study the disease's progression and potential treatments.
How long does the isoproterenol administration last?
The administration lasts for three weeks, providing a chronic model of heart failure.
What are the advantages of using an osmotic pump?
Osmotic pumps allow for continuous and controlled delivery of isoproterenol, reducing the need for frequent injections.
Who demonstrated the surgical procedure in the study?
Dr. Vincent Ren, a research scientist from Dr. Yibin Wang's laboratory, demonstrated the procedure.
What assessments are performed to evaluate the model?
Echocardiographic assessments are performed to evaluate heart function and confirm the model's effectiveness.
Is this method suitable for researchers with limited surgical experience?
Yes, the method requires less surgical expertise compared to other heart failure models.
Executive Industry Relevance
The isoproterenol-induced heart failure model via osmotic pump implantation provides a reproducible, scalable system for studying advanced cardiac remodeling in preclinical research. This approach enables target validation and mechanistic de-risking in cardiovascular drug discovery by mimicking human heart failure progression. Its applicability across >100 inbred mouse strains supports portfolio-wide target assessment and early-stage predictive confidence building.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses related to beta-adrenergic signaling and cardiac stress pathways.
- Operational Value: Supports biological de-risking through consistent induction of hypertrophy, fibrosis, and ventricular dysfunction across diverse genetic backgrounds.
Screening & Assay Development
- Scientific Value: Generates quantifiable echocardiographic endpoints (e.g., ventricular dimensions, fractional shortening) for compound screening and dose-response assessment.
- Operational Value: Standardized pump implantation and ISO dosing facilitate assay reproducibility and cross-strain comparability.
Translational & Preclinical Research
- Scientific Value: Models chronic beta-adrenergic overstimulation, aligning with pathophysiological mechanisms in human heart failure with preserved or reduced ejection fraction.
- Operational Value: Enables longitudinal monitoring via serial echocardiography, supporting go/no-go decisions based on functional and structural deterioration.
Pipeline & Workflow Integration
The model fits within the cardiovascular discovery continuum from target validation through lead optimization to preclinical efficacy testing, particularly for compounds modulating adrenergic signaling or cardiac remodeling pathways.
- Discovery Biology: Facilitates pathway interrogation and target confirmation in models of sympathetic overdrive and myocardial stress.
- Screening: Provides a stable phenotypic platform for evaluating compound effects on cardiac structure and function over 3–4 weeks.
- Analytics: Delivers quantitative, serial echocardiographic readouts enabling longitudinal assessment of therapeutic intervention.
- Translational Research: Mirrors clinical progression of adverse remodeling, supporting biomarker-aligned target prioritization.
- Enterprise Reuse: Establishes a reusable surgical and pharmacological platform applicable across multiple cardiovascular indications and target classes.
Operational & Enterprise Impact
- Scientific Value: Enhances predictive confidence by modeling human-relevant cardiac dilation, hypertrophy, and dysfunction.
- Operational Value: Requires minimal surgical expertise, enabling broad adoption across research sites and reducing inter-laboratory variability.
- Strategic Value: Improves capital efficiency by enabling early identification of ineffective compounds through functional decline metrics.
- Portfolio Impact: Supports risk-adjusted prioritization by distinguishing compounds that attenuate versus exacerbate ISO-induced remodeling.
Implementation Considerations
- Requires training in aseptic surgical techniques and osmotic pump handling.
- Depends on access to calibrated micro-syringes, blunt-tipped filling tubes, and ISO-resistant pump materials.
- Necessitates standardization of ISO concentration and volume across strains to ensure consistent pharmacokinetic exposure.
- Involves postoperative monitoring for infection and distress, particularly in genetically sensitive strains.
- Relies on echocardiography expertise for accurate longitudinal assessment of chamber dimensions and systolic function.
Biopharma FAQs
Why is continuous isoproterenol delivery important for heart failure modeling?
Continuous delivery via osmotic pump sustains beta-adrenergic stimulation over 3–4 weeks, which is necessary to induce progressive cardiac remodeling, including hypertrophy, fibrosis, and systolic dysfunction that mirror advanced human heart failure.
How does osmotic pump implantation improve model reproducibility in cardiovascular research?
Implantation ensures consistent, uninterrupted drug exposure compared to intermittent dosing, reducing variability in cardiac response and enabling reliable comparison across mouse strains and treatment groups.
What echocardiographic parameters indicate successful heart failure model induction?
Successful model induction is indicated by increased left ventricular internal diameter, elevated left ventricular mass, reduced fractional shortening, and visible chamber dilation, reflecting systolic dysfunction and adverse remodeling.
Why is weekly echocardiographic monitoring critical in the ISO-induced heart failure model?
Weekly echocardiography tracks temporal changes in wall thickness, chamber size, and function, allowing researchers to distinguish transient acute responses from sustained pathological remodeling essential for mechanistic studies.
What statistical outputs are needed to evaluate compound effects in this heart failure model?
Pre-post or treatment-control comparisons of echocardiographic endpoints (e.g., fractional shortening, ventricular dimensions) using repeated measures ANOVA or mixed-effects models are required to assess significant differences in cardiac structure and function over time.
